The company demonstrated substantial technical improvements with its next-generation Proteus platform across all key performance metrics (30x more alignments, 4.8x lower false discovery rate, 1.6-2.0x more peptides identified). The platform is not yet fully optimized, suggesting further improvements are expected. These results validate the company's R&D efforts and position Proteus as a significant advancement ahead of its Q2 2027 launch.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology